Steatosis and steatohepatitis: Complex disorders

International Journal of Molecular Sciences

Volumn 15, Issue 6, 2014, Pages 9924-9944

  Bettermann, Kira ^a   Hohensee, Tabea ^a   Haybaeck, Johannes ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ASH; NASH; Steatohepatitis; Steatosis

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA 2 MACROGLOBULIN; ALPHA TOCOPHEROL; APOLIPOPROTEIN A1; BINDING PROTEIN; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; ESTROGEN; FAS ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B KINASE BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANGANESE SUPEROXIDE DISMUTASE; MICRORNA; MICRORNA 122; MICRORNA 34A; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID DERIVATIVE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ELASTOGRAPHY; EXERCISE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KUPFFER CELL; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER FUNCTION TEST KIT; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; FATTY LIVER; GENETIC EPIGENESIS; GENETICS; GENOMICS; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FATTY LIVER; GENOMICS; HUMANS; LIVER; RISK FACTORS;

EID: 84901921708     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15069924     Document Type: Review

References (156)

1. Ludwig, J.; Viggiano, T.R.; McGill, D.B.; Oh, B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55, 434-438.
2. Angulo, P. GI epidemiology: Non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2007, 25, 883-889.
3. Law, K.; Brunt, E.M. Nonalcoholic fatty liver disease. Clin. Liver Dis. 2010, 14, 591-604.
4. Oh, M.K.; Winn, J.; Poordad, F. Review article: Diagnosis and treatment of non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 28, 503-522.
5. Younossi, Z.M.; Stepanova, M.; Afendy, M.; Fang, Y.; Younossi, Y.; Mir, H.; Srishord, M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2011, 9, 524-530.
6. Brunt, E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 195-203.
7. Aly, F.Z.; Kleiner, D.E. Update on fatty liver disease and steatohepatitis. Adv. Anat. Pathol. 2011, 18, 294-300.
8. Adams, L.A.; Lymp, J.F.; St Sauver, J.; Sanderson, S.O.; Lindor, K.D.; Feldstein, A.; Angulo, P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005, 129, 113-121.
9. Ekstedt, M.; Franzén, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865-873.
10. Ratziu, V.; Poynard, T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 2006, 44, 802-805.
11. Falck-Ytter, Y.; Younossi, Z.M.; Marchesini, G.; McCullough, A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001, 21, 17-26.
12. Powell, E.E.; Cooksley, W.G.; Hanson, R.; Searle, J.; Halliday, J.W.; Powell, L.W. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11, 74-80.
13. Schwimmer, J.B.; Deutsch, R.; Rauch, J.B.; Behling, C.; Newbury, R.; Lavine, J.E. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J. Pediatr. 2003, 143, 500-505.
14. Kelishadi, R.; Cook, S.R.; Adibi, A.; Faghihimani, Z.; Ghatrehsamani, S.; Beihaghi, A.; Salehi, H.; Khavarian, N.; Poursafa, P. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol. Metab. Syndr. 2009, 1, 29.
15. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998, 114, 842-845.
16. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846.
17. Pais, R.; Pascale, A.; Fedchuck, L.; Charlotte, F.; Poynard, T.; Ratziu, V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin. Res. Hepatol. Gastroenterol. 2011, 35, 23-28.
18. Zois, C.-D.; Baltayiannis, G.-H.; Bekiari, A.; Goussia, A.; Karayiannis, P.; Doukas, M.; Demopoulos, D.; Mitsellou, A.; Vougiouklakis, T.; Mitsi, V. et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J. Gastroenterol. 2010, 16, 3944-3949.
19. Caballería, L.; Pera, G.; Auladell, M.A.; Torán, P.; Muñoz, L.; Miranda, D.; Alumà, A.; Casas, J.D.; Sánchez, C.; Gil, D. et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol. 2010, 22, 24-32.
20. Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005, 42, 44-52.
21. Williams, C.D.; Stengel, J.; Asike, M.I.; Torres, D.M.; Shaw, J.; Contreras, M.; Landt, C.L.; Harrison, S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011, 140, 124-131.
22. Kojima, S.-I.; Watanabe, N.; Numata, M.; Ogawa, T.; Matsuzaki, S. Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background. J. Gastroenterol. 2003, 38, 954-961.
23. Amarapurkar, D.; Kamani, P.; Patel, N.; Gupte, P.; Kumar, P.; Agal, S.; Baijal, R.; Lala, S.; Chaudhary, D.; Deshpande, A. Prevalence of non-alcoholic fatty liver disease: Population based study. Ann. Hepatol. 2007, 6, 161-163.
24. Fan, J.-G.; Farrell, G.C. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009, 50, 204-210.
25. Lee, J.Y.; Kim, K.M.; Lee, S.G.; Yu, E.; Lim, Y.-S.; Lee, H.C.; Chung, Y.-H.; Lee, Y.S.; Suh, D.-J. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J. Hepatol. 2007, 47, 239-244.
26. Kallwitz, E.R.; Kumar, M.; Aggarwal, R.; Berger, R.; Layden-Almer, J.; Gupta, N.; Cotler, S.J. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: The impact of triglycerides. Dig. Dis. Sci. 2008, 53, 1358-1363.
27. Wagenknecht, L.E.; Scherzinger, A.L.; Stamm, E.R.; Hanley, A.J.G.; Norris, J.M.; Chen, Y.-D.I.; Bryer-Ash, M.; Haffner, S.M.; Rotter, J.I. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009, 17, 1240-1246.
28. Fischer, G.E.; Bialek, S.P.; Homan, C.E.; Livingston, S.E.; McMahon, B.J. Chronic liver disease among Alaska-Native people, 2003-2004. Am. J. Gastroenterol. 2009, 104, 363-370.
29. Bialek, S.R.; Redd, J.T.; Lynch, A.; Vogt, T.; Lewis, S.; Wilson, C.; Bell, B.P. Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003. J. Clin. Gastroenterol. 2008, 42, 949-954.
30. Devadason, C.A.; Scheimann, A.O. Overview of screening methods for fatty liver disease in children. World J. Hepatol. 2012, 4, 1-4.
31. Hudson, O.D.; Nunez, M.; Shaibi, G.Q. Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes. BMC Pediatr. 2012, 12, 174.
32. Schwimmer, J.B.; McGreal, N.; Deutsch, R.; Finegold, M.J.; Lavine, J.E. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005, 115, e561-e565.
33. Chen, Z.; Chen, L.; Dai, H.; Chen, J.; Fang, L. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J. Zhejiang Univ. Sci. B 2008, 9, 616-622.
34. Sorrentino, P.; Tarantino, G.; Conca, P.; Perrella, A.; Terracciano, M.L.; Vecchione, R.; Gargiulo, G.; Gennarelli, N.; Lobello, R. Silent non-alcoholic fatty liver disease-a clinical-histological study. J. Hepatol. 2004, 41, 751-757.
35. Papatheodoridis, G.V.; Goulis, J.; Christodoulou, D.; Manolakopoulos, S.; Raptopoulou, M.; Andrioti, E.; Alexandropoulos, N.; Savvidou, S.; Papachristou, A.; Zervou, E. et al. High prevalence of elevated liver enzymes in blood donors: Associations with male gender and central adiposity. Eur. J. Gastroenterol. Hepatol. 2007, 19, 281-287.
36. Carr, M.C.; Ayyobi, A.F.; Murdoch, S.J.; Deeb, S.S.; Brunzell, J.D. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 667-673.
37. Rivera, C.A. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiol. Off. J. Int. Soc. Pathophysiol. 2008, 15, 109-114.
38. Elbers, J.M.; Asscheman, H.; Seidell, J.C.; Gooren, L.J. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am. J. Physiol. 1999, 276, E317-E325.
39. Haarbo, J.; Marslew, U.; Gotfredsen, A.; Christiansen, C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991, 40, 1323-1326.
40. Toth, M.J.; Tchernof, A.; Sites, C.K.; Poehlman, E.T. Effect of menopausal status on body composition and abdominal fat distribution. Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes. 2000, 24, 226-231.
41. Machado, M.; Marques-Vidal, P.; Cortez-Pinto, H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 2006, 45, 600-606.
42. Colicchio, P.; Tarantino, G.; del Genio, F.; Sorrentino, P.; Saldalamacchia, G.; Finelli, C.; Conca, P.; Contaldo, F.; Pasanisi, F. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann. Nutr. Metab. 2005, 49, 289-295.
43. Beymer, C.; Kowdley, K.V.; Larson, A.; Edmonson, P.; Dellinger, E.P.; Flum, D.R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch. Surg. Chic. Ill 1960 2003, 138, 1240-1244.
44. Boza, C.; Riquelme, A.; Ibañez, L.; Duarte, I.; Norero, E.; Viviani, P.; Soza, A.; Fernandez, J.I.; Raddatz, A.; Guzman, S. et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes. Surg. 2005, 15, 1148-1153.
45. Abrams, G.A.; Kunde, S.S.; Lazenby, A.J.; Clements, R.H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004, 40, 475-483.
46. Bugianesi, E.; Gastaldelli, A.; Vanni, E.; Gambino, R.; Cassader, M.; Baldi, S.; Ponti, V.; Pagano, G.; Ferrannini, E.; Rizzetto, M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005, 48, 634-642.
47. Stranges, S.; Dorn, J.M.; Muti, P.; Freudenheim, J.L.; Farinaro, E.; Russell, M.; Nochajski, T.H.; Trevisan, M. Body fat distribution, relative weight, and liver enzyme levels: A population-based study. Hepatology 2004, 39, 754-763.
48. Lomonaco, R.; Ortiz-Lopez, C.; Orsak, B.; Webb, A.; Hardies, J.; Darland, C.; Finch, J.; Gastaldelli, A.; Harrison, S.; Tio, F. et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012, 55, 1389-1397.
49. Musso, G.; Cassader, M.; de Michieli, F.; Rosina, F.; Orlandi, F.; Gambino, R. Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012, 56, 933-942.
50. Zhan, Y.-T.; An, W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J. Gastroenterol. 2010, 16, 4652-4660.
51. Copaci, I.; Micu, L.; Voiculescu, M. The role of cytokines in non-alcoholic steatohepatitis. A review. J. Gastrointest. Liver Dis. 2006, 15, 363-373.
52. Syn, W.-K.; Jung, Y.; Omenetti, A.; Abdelmalek, M.; Guy, C.D.; Yang, L.; Wang, J.; Witek, R.P.; Fearing, C.M.; Pereira, T.A. et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137, 1478-1488.
53. Bohinc, B.N.; Diehl, A.M. Mechanisms of disease progression in NASH: New paradigms. Clin. Liver Dis. 2012, 16, 549-565.
54. Guy, C.D.; Suzuki, A.; Zdanowicz, M.; Abdelmalek, M.F.; Burchette, J.; Unalp, A.; Diehl, A.M. NASH CRN Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 2012, 55, 1711-1721.
55. Cheung, O.; Sanyal, A.J. Role of microRNAs in non-alcoholic steatohepatitis. Curr. Pharm. Des. 2010, 16, 1952-1957.
56. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438, 685-689.
57. Cheung, O.; Puri, P.; Eicken, C.; Contos, M.J.; Mirshahi, F.; Maher, J.W.; Kellum, J.M.; Min, H.; Luketic, V.A.; Sanyal, A.J. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48, 1810-1820.
58. Nakanishi, N.; Nakagawa, Y.; Tokushige, N.; Aoki, N.; Matsuzaka, T.; Ishii, K.; Yahagi, N.; Kobayashi, K.; Yatoh, S.; Takahashi, A. et al. The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochem. Biophys. Res. Commun. 2009, 385, 492-496.
59. Li, W.-Q.; Chen, C.; Xu, M.-D.; Guo, J.; Li, Y.-M.; Xia, Q.-M.; Liu, H.-M.; He, J.; Yu, H.-Y.; Zhu, L. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J. 2011, 278, 1522-1532.
60. Castro, R.E.; Ferreira, D.M.S.; Afonso, M.B.; Borralho, P.M.; Machado, M.V.; Cortez-Pinto, H.; Rodrigues, C.M.P. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 2013, 58, 119-125.
61. Kawaguchi, T.; Sumida, Y.; Umemura, A.; Matsuo, K.; Takahashi, M.; Takamura, T.; Yasui, K.; Saibara, T.; Hashimoto, E.; Kawanaka, M. et al. Japan Study Group of Nonalcoholic Fatty Liver Disease. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012, 7, e38322.
62. Rotman, Y.; Koh, C.; Zmuda, J.M.; Kleiner, D.E.; Liang, T.J. NASH CRN The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52, 894-903.
63. Wang, C.-W.; Lin, H.-Y.; Shin, S.-J.; Yu, M.-L.; Lin, Z.-Y.; Dai, C.-Y.; Huang, J.-F.; Chen, S.-C.; Li, S.S.-L.; Chuang, W.-L. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. Off. J. Int. Assoc. Study Liver 2011, 31, 1326-1331.
64. Al-Serri, A.; Anstee, Q.M.; Valenti, L.; Nobili, V.; Leathart, J.B.S.; Dongiovanni, P.; Patch, J.; Fracanzani, A.; Fargion, S.; Day, C.P. et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. J. Hepatol. 2012, 56, 448-454.
65. Kotronen, A.; Johansson, L.E.; Johansson, L.M.; Roos, C.; Westerbacka, J.; Hamsten, A.; Bergholm, R.; Arkkila, P.; Arola, J.; Kiviluoto, T. et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52, 1056-1060.
66. Johansson, L.E.; Hoffstedt, J.; Parikh, H.; Carlsson, E.; Wabitsch, M.; Bondeson, A.-G.; Hedenbro, J.; Tornqvist, H.; Groop, L.; Ridderstråle, M. Variation in the adiponutrin gene influences its expression and associates with obesity. Diabetes 2006, 55, 826-833.
67. Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nuremberg, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40, 1387-1395.
68. Mofrad, P.; Contos, M.J.; Haque, M.; Sargeant, C.; Fisher, R.A.; Luketic, V.A.; Sterling, R.K.; Shiffman, M.L.; Stravitz, R.T.; Sanyal, A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37, 1286-1292.
69. Joseph, A.E.; Dewbury, K.C.; McGuire, P.G. Ultrasound in the detection of chronic liver disease (the "bright liver"). Br. J. Radiol. 1979, 52, 184-188.
70. Bydder, M.; Yokoo, T.; Hamilton, G.; Middleton, M.S.; Chavez, A.D.; Schwimmer, J.B.; Lavine, J.E.; Sirlin, C.B. Relaxation effects in the quantification of fat using gradient echo imaging. Magn. Reson. Imaging 2008, 26, 347-359.
71. Hussain, H.K.; Chenevert, T.L.; Londy, F.J.; Gulani, V.; Swanson, S.D.; McKenna, B.J.; Appelman, H.D.; Adusumilli, S.; Greenson, J.K.; Conjeevaram, H.S. Hepatic fat fraction: MR imaging for quantitative measurement and display-Early experience. Radiology 2005, 237, 1048-1055.
72. Reeder, S.B.; Ranallo, F.; Taylor, A.J. CT and MRI for determining hepatic fat content. Am. J. Roentgenol. 2008, 190, W167; author reply W168.
73. Fitzpatrick, E.; Quaglia, A.; Vimalesvaran, S.; Basso, M.S.; Dhawan, A. Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease. J. Pediatr. Gastroenterol. Nutr. 2013, 56, 72-76.
74. Yin, M.; Talwalkar, J.A.; Glaser, K.J.; Manduca, A.; Grimm, R.C.; Rossman, P.J.; Fidler, J.L.; Ehman, R.L. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2007, 5, 1207-1213.
75. Ratziu, V.; Massard, J.; Charlotte, F.; Messous, D.; Imbert-Bismut, F.; Bonyhay, L.; Tahiri, M.; Munteanu, M.; Thabut, D.; Cadranel, J.F. et al. LIDO Study Group and CYTOL Study Group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006, 6, 6.
76. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Investig. 2004, 114, 147-152.
77. Sozio, M.; Liangpunsakul, S.; Crabb, D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin. Liver Dis. 2010, 30, 378-390.
78. Tiniakos, D.G.; Vos, M.B.; Brunt, E.M. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu. Rev. Pathol. 2010, 5, 145-171.
79. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112, 1821-1830.
80. Lafontan, M. Fat cells: Afferent and efferent messages define new approaches to treat obesity. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 119-146.
81. Fontana, L.; Eagon, J.C.; Trujillo, M.E.; Scherer, P.E.; Klein, S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56, 1010-1013.
82. Day, C.P. From fat to inflammation. Gastroenterology 2006, 130, 207-210.
83. Diehl, A.M.; Li, Z.P.; Lin, H.Z.; Yang, S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54, 303-306.
84. Van der Poorten, D.; Milner, K.-L.; Hui, J.; Hodge, A.; Trenell, M.I.; Kench, J.G.; London, R.; Peduto, T.; Chisholm, D.J.; George, J. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48, 449-457.
85. Beasley, L.E.; Koster, A.; Newman, A.B.; Javaid, M.K.; Ferrucci, L.; Kritchevsky, S.B.; Kuller, L.H.; Pahor, M.; Schaap, L.A.; Visser, M. et al. Health ABC study inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity 2009, 17, 1062-1069.
86. Gabriely, I.; Ma, X.H.; Yang, X.M.; Atzmon, G.; Rajala, M.W.; Berg, A.H.; Scherer, P.; Rossetti, L.; Barzilai, N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging an adipokine-mediated process? Diabetes 2002, 51, 2951-2958.
87. Kadowaki, T.; Yamauchi, T.; Kubota, N.; Hara, K.; Ueki, K.; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Investig. 2006, 116, 1784-1792.
88. Goldstein, B.J.; Scalia, R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 2004, 89, 2563-2568.
89. Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.; Goodman, Z.; Chandhoke, V. et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 27, 412-421.
90. Louthan, M.V.; Barve, S.; McClain, C.J.; Joshi-Barve, S. Decreased serum adiponectin: An early event in pediatric nonalcoholic fatty liver disease. J. Pediatr. 2005, 147, 835-838.
91. Crespo, J.; Fernández-Gil, P.; Hernández-Guerra, M.; Cayón, A.; Mayorga, M.; Domínguez-Diez, A.; Fernández-Escalante, J.C.; Pons-Romero, F. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes. Surg. 2001, 11, 254-257.
92. Hui, J.M.; Hodge, A.; Farrell, G.C.; Kench, J.G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 2004, 40, 46-54.
93. Diehl, A.M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin. Liver Dis. 2004, 8, 619-638.
94. Hayden, M.S.; Ghosh, S. Signaling to NF-κB. Genes Dev. 2004, 18, 2195-2224.
95. Palmer, M.; Schaffner, F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99, 1408-1413.
96. Park, H.S.; Kim, M.W.; Shin, E.S. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J. Korean Med. Sci. 1995, 10, 414-421.
97. Ueno, T.; Sugawara, H.; Sujaku, K.; Hashimoto, O.; Tsuji, R.; Tamaki, S.; Torimura, T.; Inuzuka, S.; Sata, M.; Tanikawa, K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997, 27, 103-107.
98. Harrison, S.A.; Fecht, W.; Brunt, E.M.; Neuschwander-Tetri, B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009, 49, 80-86.
99. Andersen, T.; Gluud, C.; Franzmann, M.B.; Christoffersen, P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. 1991, 12, 224-229.
100. Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59-69.
101. Narasimhan, S.; Gokulakrishnan, K.; Sampathkumar, R.; Farooq, S.; Ravikumar, R.; Mohan, V.; Balasubramanyam, M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin. Biochem. 2010, 43, 815-821.
102. Rezazadeh, A.; Yazdanparast, R.; Molaei, M. Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. J. Biomed. Sci. 2012, 19, 26.
103. Lavine, J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J. Pediatr. 2000, 136, 734-738.
104. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A. et al. NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675-1685.
105. Tiikkainen, M.; Häkkinen, A.-M.; Korsheninnikova, E.; Nyman, T.; Mäkimattila, S.; Yki-Järvinen, H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53, 2169-2176.
106. Lehtovirta, M.; Forsén, B.; Gullström, M.; Häggblom, M.; Eriksson, J.G.; Taskinen, M.R.; Groop, L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet. Med. J. Br. Diabet. Assoc. 2001, 18, 578-583.
107. Shields, W.W.; Thompson, K.E.; Grice, G.A.; Harrison, S.A.; Coyle, W.J. The effect of Metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A pilot trial. Ther. Adv. Gastroenterol. 2009, 2, 157-163.
108. Omer, Z.; Cetinkalp, S.; Akyildiz, M.; Yilmaz, F.; Batur, Y.; Yilmaz, C.; Akarca, U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2010, 22, 18-23.
109. Neuschwander-Tetri, B.A.; Brunt, E.M.; Wehmeier, K.R.; Oliver, D.; Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003, 38, 1008-1017.
110. Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J.; Hardies, J.; Balas, B.; Gastaldelli, A.; Tio, F.; Pulcini, J. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355, 2297-2307.
111. Masterton, G.S.; Plevris, J.N.; Hayes, P.C. Review article: Omega-3 fatty acids-A promising novel therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2010, 31, 679-692.
112. Li, W.; Zheng, L.; Sheng, C.; Cheng, X.; Qing, L.; Qu, S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011, 10, 49.
113. Shoelson, S.E.; Lee, J.; Yuan, M. Inflammation and the IKKβ/IκB/NF-κB axis in obesity-and diet-induced insulin resistance. Int. J. Obes. 2003, 27, S49-S52.
114. Arkan, M.C.; Hevener, A.L.; Greten, F.R.; Maeda, S.; Li, Z.-W.; Long, J.M.; Wynshaw-Boris, A.; Poli, G.; Olefsky, J.; Karin, M. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11, 191-198.
115. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson, S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 2005, 11, 183-190.
116. Wueest, S.; Rapold, R.A.; Schumann, D.M.; Rytka, J.M.; Schildknecht, A.; Nov, O.; Chervonsky, A.V.; Rudich, A.; Schoenle, E.J.; Donath, M.Y. et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J. Clin. Investig. 2010, 120, 191-202.
117. Seki, E.; Brenner, D.A. Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 2008, 48, 322-335.
118. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761-1772.
119. Wree, A.; Broderick, L.; Canbay, A.; Hoffman, H.M.; Feldstein, A.E. From NAFLD to NASH to cirrhosis-New insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 627-636.
120. Rivera, C.A.; Adegboyega, P.; van Rooijen, N.; Tagalicud, A.; Allman, M.; Wallace, M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47, 571-579.
121. Yoshimoto, S.; Loo, T.M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.; Hattori, M. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499, 97-101.
122. Syn, W.-K.; Teaberry, V.; Choi, S.S.; Diehl, A.M. Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin. Liver Dis. 2009, 29, 200-210.
123. Chen, G.; Liang, G.; Ou, J.; Goldstein, J.L.; Brown, M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. USA 2004, 101, 11245-11250.
124. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125-1131.
125. Nakamuta, M.; Kohjima, M.; Morizono, S.; Kotoh, K.; Yoshimoto, T.; Miyagi, I.; Enjoji, M. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2005, 16, 631-635.
126. Kohjima, M.; Enjoji, M.; Higuchi, N.; Kato, M.; Kotoh, K.; Yoshimoto, T.; Fujino, T.; Yada, M.; Yada, R.; Harada, N. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20, 351-358.
127. Higuchi, N.; Kato, M.; Shundo, Y.; Tajiri, H.; Tanaka, M.; Yamashita, N.; Kohjima, M.; Kotoh, K.; Nakamuta, M.; Takayanagi, R. et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2008, 38, 1122-1129.
128. Caballero, F.; Fernández, A.; de Lacy, A.M.; Fernández-Checa, J.C.; Caballería, J.; García-Ruiz, C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009, 50, 789-796.
129. Shimomura, I.; Bashmakov, Y.; Horton, J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 1999, 274, 30028-30032.
130. Shimomura, I.; Matsuda, M.; Hammer, R.E.; Bashmakov, Y.; Brown, M.S.; Goldstein, J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 2000, 6, 77-86.
131. Towle, H.C.; Kaytor, E.N.; Shih, H.-M. Regulation of the expression of lipogenic enzyme genes by carbohydrate. Annu. Rev. Nutr. 1997, 17, 405-433.
132. Iizuka, K.; Horikawa, Y. ChREBP: A glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr. J. 2008, 55, 617-624.
133. Iizuka, K.; Bruick, R.K.; Liang, G.; Horton, J.D.; Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 2004, 101, 7281-7286.
134. Iizuka, K.; Miller, B.; Uyeda, K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E358-E364.
135. Gyamfi, M.A.; Wan, Y.-J.Y. Pathogenesis of alcoholic liver disease: The role of nuclear receptors. Exp. Biol. Med. 2010, 235, 547-560.
136. Joseph, S.B.; Laffitte, B.A.; Patel, P.H.; Watson, M.A.; Matsukuma, K.E.; Walczak, R.; Collins, J.L.; Osborne, T.F.; Tontonoz, P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by Liver X receptors. J. Biol. Chem. 2002, 277, 11019-11025.
137. Zhang, Y.; Yin, L.; Hillgartner, F.B. SREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCα transcription in hepatocytes. J. Lipid Res. 2003, 44, 356-368.
138. Cha, J.-Y.; Repa, J.J. The Liver X Receptor (LXR) and hepatic lipogenesis. The Carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 2007, 282, 743-751.
139. Mitro, N.; Mak, P.A.; Vargas, L.; Godio, C.; Hampton, E.; Molteni, V.; Kreusch, A.; Saez, E. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445, 219-223.
140. Janowski, B.A.; Grogan, M.J.; Jones, S.A.; Wisely, G.B.; Kliewer, S.A.; Corey, E.J.; Mangelsdorf, D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl. Acad. Sci. USA 1999, 96, 266-271.
141. Janowski, B.A.; Willy, P.J.; Devi, T.R.; Falck, J.R.; Mangelsdorf, D.J. An oxysterol signaling pathway mediated by the nuclear receptor LXRα. Nature 1996, 383, 728-731.
142. Sozio, M.; Crabb, D.W. Alcohol and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E10-E16.
143. You, M.; Matsumoto, M.; Pacold, C.M.; Cho, W.K.; Crabb, D.W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004, 127, 1798-1808.
144. García-Villafranca, J.; Guillén, A.; Castro, J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008, 90, 460-466.
145. Song, Z.; Deaciuc, I.; Zhou, Z.; Song, M.; Chen, T.; Hill, D.; McClain, C.J. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G894-G902.
146. Yang, J.; Maika, S.; Craddock, L.; King, J.A.; Liu, Z.-M. Chronic activation of AMP-activated protein kinase-α1 in liver leads to decreased adiposity in mice. Biochem. Biophys. Res. Commun. 2008, 370, 248-253.
147. Shang, J.; Chen, L.; Xiao, F.; Sun, H.; Ding, H.; Xiao, H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29, 698-706.
148. Wada, S.; Yamazaki, T.; Kawano, Y.; Miura, S.; Ezaki, O. Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice. J. Hepatol. 2008, 49, 441-450.
149. Kallwitz, E.R.; McLachlan, A.; Cotler, S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 2008, 14, 22-28.
150. Kim, J.B.; Spiegelman, B.M. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996, 10, 1096-1107.
151. Gavrilova, O.; Haluzik, M.; Matsusue, K.; Cutson, J.J.; Johnson, L.; Dietz, K.R.; Nicol, C.J.; Vinson, C.; Gonzalez, F.J.; Reitman, M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278, 34268-34276.
152. Savage, D.B.; Tan, G.D.; Acerini, C.L.; Jebb, S.A.; Agostini, M.; Gurnell, M.; Williams, R.L.; Umpleby, A.M.; Thomas, E.L.; Bell, J.D. et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 2003, 52, 910-917.
153. Molnar, A.; Haybaeck, J.; Lackner, C.; Strnad, P. The cytoskeleton in nonalcoholic steatohepatitis: 100 years old but still youthful. Expert Rev. Gastroenterol. Hepatol. 2011, 5, 167-177.
154. Haybaeck, J.; Stumptner, C.; Thueringer, A.; Kolbe, T.; Magin, T.M.; Hesse, M.; Fickert, P.; Tsybrovskyy, O.; Müller, H.; Trauner, M. et al. Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Lab. Investig. J. Tech. Methods Pathol. 2012, 92, 857-867.
155. Denk, H.; Stumptner, C.; Fuchsbichler, A.; Zatloukal, K. Alkoholische und nichtalkoholische Steatohepatitis. Pathology 2001, 22, 388-398.
156. Garcia-Ruiz, C.; Marí, M.; Colell, A.; Morales, A.; Fernandez-Checa, J.C. Metabolic therapy: Lessons from liver diseases. Curr. Pharm. Des. 2011, 17, 3933-3944.